ZA200707020B - Combination of EGF/GHRP-6 for neuroregeneration of central nervous system following autoimmune damage - Google Patents
Combination of EGF/GHRP-6 for neuroregeneration of central nervous system following autoimmune damageInfo
- Publication number
- ZA200707020B ZA200707020B ZA200707020A ZA200707020A ZA200707020B ZA 200707020 B ZA200707020 B ZA 200707020B ZA 200707020 A ZA200707020 A ZA 200707020A ZA 200707020 A ZA200707020 A ZA 200707020A ZA 200707020 B ZA200707020 B ZA 200707020B
- Authority
- ZA
- South Africa
- Prior art keywords
- nervous system
- central nervous
- neuroregeneration
- ghrp
- egf
- Prior art date
Links
- 210000003169 central nervous system Anatomy 0.000 title abstract 3
- 230000001363 autoimmune Effects 0.000 title abstract 2
- 230000035771 neuroregeneration Effects 0.000 title abstract 2
- WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 title 1
- 108010015153 growth hormone releasing hexapeptide Proteins 0.000 title 1
- 208000016192 Demyelinating disease Diseases 0.000 abstract 1
- 206010012305 Demyelination Diseases 0.000 abstract 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 abstract 1
- 101800003838 Epidermal growth factor Proteins 0.000 abstract 1
- 102000018997 Growth Hormone Human genes 0.000 abstract 1
- 108010051696 Growth Hormone Proteins 0.000 abstract 1
- 229940116977 epidermal growth factor Drugs 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20050043A CU23529A1 (es) | 2005-03-02 | 2005-03-02 | Combinación de egf/ghrp-6 para la neuroregeneración del sistema nervioso central posterior al dano autoinmune |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200707020B true ZA200707020B (en) | 2009-08-26 |
Family
ID=40280698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200707020A ZA200707020B (en) | 2005-03-02 | 2007-08-21 | Combination of EGF/GHRP-6 for neuroregeneration of central nervous system following autoimmune damage |
Country Status (18)
Country | Link |
---|---|
US (1) | US20100093616A1 (pt) |
EP (1) | EP1870106B1 (pt) |
JP (1) | JP5001180B2 (pt) |
KR (1) | KR101255200B1 (pt) |
CN (1) | CN101180044B (pt) |
AT (1) | ATE431743T1 (pt) |
AU (1) | AU2006220154B2 (pt) |
BR (1) | BRPI0607844B8 (pt) |
CA (1) | CA2600628C (pt) |
CU (1) | CU23529A1 (pt) |
DE (1) | DE602006006903D1 (pt) |
ES (1) | ES2327562T3 (pt) |
MX (1) | MX2007010717A (pt) |
MY (1) | MY142494A (pt) |
PT (1) | PT1870106E (pt) |
RU (1) | RU2403913C2 (pt) |
WO (1) | WO2006092106A2 (pt) |
ZA (1) | ZA200707020B (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2604943T3 (es) | 2007-02-09 | 2017-03-10 | Ocera Therapeutics, Inc. | Moduladores macrocíclicos del receptor de la grelina y procedimientos de uso de los mismos |
CU24591B1 (es) | 2018-08-21 | 2022-04-07 | Ct Ingenieria Genetica Biotecnologia | Kit para la restauración del daño cerebral que comprende el factor de crecimiento epidérmico y el hexapéptido secretagogo de la hormona de crecimiento |
EP3721896B1 (en) | 2019-04-08 | 2023-11-29 | Giuseppe Scalabrino | Epidermal growth factor (egf) and variants thereof for treating or preventing inflammatory demyelinating disorders |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9804064D0 (sv) * | 1998-11-25 | 1998-11-25 | A & Science Invest Ab | Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells |
CU23157A1 (es) * | 2001-01-03 | 2006-07-18 | Ct Ingenieria Genetica Biotech | COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL |
AR036400A1 (es) * | 2001-08-30 | 2004-09-08 | Stem Cell Therapeutics Inc | Regulacion combinada de la produccion de celulas nerviosas. |
HK1077740A1 (en) * | 2001-12-20 | 2006-02-24 | Ct Ingenieria Genetica Biotech | Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation |
EP1506997A1 (en) * | 2003-08-14 | 2005-02-16 | NeuroProgen GmbH Leipzig | Method of generating neural stem cells |
-
2005
- 2005-03-02 CU CU20050043A patent/CU23529A1/es active IP Right Grant
-
2006
- 2006-02-24 BR BRPI0607844A patent/BRPI0607844B8/pt not_active IP Right Cessation
- 2006-02-24 KR KR1020077022024A patent/KR101255200B1/ko active IP Right Grant
- 2006-02-24 CN CN2006800139592A patent/CN101180044B/zh active Active
- 2006-02-24 MX MX2007010717A patent/MX2007010717A/es active IP Right Grant
- 2006-02-24 DE DE602006006903T patent/DE602006006903D1/de active Active
- 2006-02-24 ES ES06705745T patent/ES2327562T3/es active Active
- 2006-02-24 WO PCT/CU2006/000001 patent/WO2006092106A2/es active Application Filing
- 2006-02-24 EP EP06705745A patent/EP1870106B1/en active Active
- 2006-02-24 RU RU2007136280/15A patent/RU2403913C2/ru active
- 2006-02-24 AU AU2006220154A patent/AU2006220154B2/en not_active Ceased
- 2006-02-24 PT PT06705745T patent/PT1870106E/pt unknown
- 2006-02-24 MY MYPI20060792A patent/MY142494A/en unknown
- 2006-02-24 US US11/885,330 patent/US20100093616A1/en not_active Abandoned
- 2006-02-24 JP JP2007557312A patent/JP5001180B2/ja not_active Expired - Fee Related
- 2006-02-24 AT AT06705745T patent/ATE431743T1/de not_active IP Right Cessation
- 2006-02-24 CA CA2600628A patent/CA2600628C/en not_active Expired - Fee Related
-
2007
- 2007-08-21 ZA ZA200707020A patent/ZA200707020B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CN101180044B (zh) | 2010-12-08 |
MX2007010717A (es) | 2007-10-12 |
CA2600628A1 (en) | 2006-09-08 |
DE602006006903D1 (de) | 2009-07-02 |
JP2008531607A (ja) | 2008-08-14 |
JP5001180B2 (ja) | 2012-08-15 |
CU23529A1 (es) | 2010-06-17 |
US20100093616A1 (en) | 2010-04-15 |
PT1870106E (pt) | 2009-08-25 |
BRPI0607844B1 (pt) | 2018-08-28 |
KR101255200B1 (ko) | 2013-04-23 |
WO2006092106A2 (es) | 2006-09-08 |
RU2403913C2 (ru) | 2010-11-20 |
ES2327562T3 (es) | 2009-10-30 |
EP1870106B1 (en) | 2009-05-20 |
KR20070107790A (ko) | 2007-11-07 |
WO2006092106A3 (es) | 2006-12-14 |
BRPI0607844B8 (pt) | 2021-05-25 |
RU2007136280A (ru) | 2009-04-10 |
BRPI0607844A2 (pt) | 2010-10-19 |
AU2006220154B2 (en) | 2010-05-27 |
EP1870106A2 (en) | 2007-12-26 |
AU2006220154A1 (en) | 2006-09-08 |
MY142494A (en) | 2010-11-30 |
ATE431743T1 (de) | 2009-06-15 |
CA2600628C (en) | 2013-04-09 |
CN101180044A (zh) | 2008-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2496892T3 (es) | Formulaciones para el tratamiento de trastornos del tracto respiratorio superior | |
AR109170A2 (es) | Esfingomielinasa ácida para uso en la prevención o el tratamiento de la enfermedad de niemann-pick a o b en un paciente | |
MX2019011592A (es) | Peptidos y analogos de peptidos protectores de los tejidos para evitar y tratar padecimientos y desordenes asociados con daño de los tejidos. | |
HK1121172A1 (en) | Compounds for enzyme inhibition | |
MX370543B (es) | Profarmacos neutralizantes del factor de crecimiento endotelial vascular para el tratamiento de afecciones oculares. | |
EA200970287A1 (ru) | Способы, соединения, композиции и носители, подходящие для доставки 3-амино-1-пропансульфоновой кислоты | |
BRPI0515118A (pt) | conjugados de hormÈnio do crescimento humano com polietileno glicol | |
EP3211001A3 (en) | Superagonists and antagonists of interleukin-2 | |
WO2007014258A3 (en) | Growth hormone secretagogues | |
CU23734A1 (es) | Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas | |
CY1112082T1 (el) | Υγρη φαρμακοτεχνικη μορφη fsh | |
MX361858B (es) | Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares. | |
MX2018006299A (es) | Analogos de peptido de la hormona de estimulacion de alfa-melanocito. | |
GT201100336A (es) | Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas | |
ZA200707020B (en) | Combination of EGF/GHRP-6 for neuroregeneration of central nervous system following autoimmune damage | |
PL2091526T3 (pl) | Leczenie całościowych zaburzeń rozwojowych | |
WO2013173827A3 (en) | Methods and compositions for inhibiting diseases of the central nervous system | |
WO2011076209A3 (en) | Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue | |
WO2007130509A3 (en) | Pyrroloquinoline quinones and use thereof | |
HK1216993A1 (zh) | 用於治療中樞神經系統疾病的含有低濃度唾液酸的重組人紅細胞生成素的鼻用製劑 | |
MX2015006997A (es) | Composicion farmaceutica. | |
EP2578232A4 (en) | TREATMENT FOR AUTOIMMUN DISEASES AND ALLERGIC DISEASES | |
PL1612210T3 (pl) | Nowe analogi nitrobenzylotioinozyny | |
WO2012030949A3 (en) | B2-glycoprotein i peptide inhibitors | |
CO2024002715A2 (es) | Formulaciones de radiprodil |